Indaptus Therapeutics, Inc. 2025 Annual Report: Company Overview, Risks, Investment Transaction, and Regulatory Compliance

2. Lazar Investment Transaction and Control Change

In December 2025, Indaptus executed a strategic investment transaction (the “Lazar Investment Transaction”). As a result, Mr. Lazar has assumed significant control and influence over the company’s management and strategic direction.
The Board and management team were significantly changed, and further changes may occur if a “Post-Investment Transaction” (e.g., merger or acquisition) is completed.
The company is actively pursuing a merger or acquisition (Post-Investment Transaction) but has not finalized any such deal as of the report date. Failure to consummate a suitable transaction could jeopardize anticipated benefits from the Lazar deal.

3. Substantial Equity and Warrant Issuances & Repricing

In 2024 and 2025, Indaptus issued substantial amounts of common stock, preferred stock, and warrants in several financing rounds, including:
- June 2025: Private placement of \$5.7 million in convertible notes (including CEO participation), converting into 501,566 shares of common stock and pre-funded warrants for another 190,795 shares, plus 1,384,722 warrants (originally at \$8.30/share).
- January 2025: Sale of 75,335 shares and warrants for another 75,335 shares, with Paulson Investment Company as placement agent.
- August 2024: Registered direct offering of 58,708 shares and warrants for 58,708 more, at \$51.1 per unit.
February 2026 Warrant Repricing: The company repriced 913,638 warrants (originally \$8.30–\$47.60 exercise price) and unilaterally reduced the exercise price of an additional 762,787 warrants and agent warrants to \$1.75 per share. This could substantially increase dilution risk for existing shareholders if warrants are exercised at the new, lower price.

4. Critical Financial Risks and Going Concern Doubts

Indaptus is a clinical-stage company with a limited operating history, no current profitability, and explicit doubt about its ability to continue as a going concern.
The company requires additional capital to continue operations. If it cannot raise funds on acceptable terms, it may be forced to curtail or eliminate research programs, product development, and commercialization efforts.
Raising new capital via equity will cause further dilution and may require the company to relinquish rights to technology or product candidates.
The company’s financial statements do not reflect any correction of previously issued statements or any restatements requiring recovery of executive compensation.

5. Regulatory and Operational Risks

Indaptus’ product candidates are in early development and may cause side effects that could delay or prevent regulatory approval or commercialization.
The company faces risks related to intellectual property, compliance with complex U.S. and foreign healthcare regulations, data privacy, cybersecurity, and the requirements of being a public company.

6. Market and Listing Risks

The market price of Indaptus’ common stock is highly volatile, and investors could lose their entire investment.
The company may not meet Nasdaq’s minimum market value requirements for continued listing.

View Indaptus Therapeutics, Inc. Historical chart here